CA2257254C - Antibiotic producing microbe - Google Patents
Antibiotic producing microbe Download PDFInfo
- Publication number
- CA2257254C CA2257254C CA002257254A CA2257254A CA2257254C CA 2257254 C CA2257254 C CA 2257254C CA 002257254 A CA002257254 A CA 002257254A CA 2257254 A CA2257254 A CA 2257254A CA 2257254 C CA2257254 C CA 2257254C
- Authority
- CA
- Canada
- Prior art keywords
- cyclosporin
- tolypocladium
- microbe
- poli
- production
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
- C07K7/645—Cyclosporins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/911—Microorganisms using fungi
Abstract
A cyclosporin-producing microbe is described. A process for the production of cyclosporin, comprising culturing the microbe and recovering the desired form of cyclosporin produced, is described.
Description
CA 022~72~4 l998-l2-04 W097/46580 PCT~B97/00654 ANTIBIOTIC PRODUCING MICROBE
Field of the In~ention The present invention relates to a novel cyclosporin-producing microbe, apparently a member of the fungal genus Tolypocladium, and to a process for producing cyclosporins by the fermentation of this microbe.
Back~round of the In~ention Cyclosporins are a group o~ non-polar cyclic oligopeptide compounds having immunosuppressant activity. Cyclosporins are produced by fungal fermentation. Cyclosporins have been employed for several years to combat rejection of transplanted organs and tissues in humans. Recently, investigators have been seeking additional therapeutic applications for the drug.
At least nine different cyclosporins are produced by the fungi, including cyclosporin A, B, C, D, E, F, G, H, and I, all having varying amino acid composition. Cyclosporin A is the major component and currently enjoys the most wide-spread clinical use.
See, e.g., Ruegger et al., Helv. Chim. Acta 59:1075 (1976); Traber et al., Helv. Chim. Acta 60:1568 (1977);
Rehacek and De-xiu, Process Biochem 26:157 (1991).
Cyclosporin A is commercially available under the tradename SANDIMMUNE~ from Sandoz Corp.
Cyclosporins were originally isolated as - metabolites produced by fungal strains of Cylindrocarpon lucidum Booth and Tolypocladium inflatum ~ Gams (Gams, Persoonia 6:185 (1971)), isolated from soil samples from the United States of America and Norway.
T. inflatum is also known as Tolypocladium niveum.
Isaac et al., Antimicro. Agents Chemother. 34:121 - CONFIRM~ION COPY
CA 022~72~4 1998-12-04 W097/46580 PCTnB97/00654 (1990). (The genus Tolypocladium was first described by Gams, Persoonia, 6 :185 (1971); the genus name Beauveria has been used synonymously with Tolypocladium.) Species of Tolypocladium are typically slow in growth and form white, flocculent colonies with a large amount of spores.
A production strain of Tolypocladium (Tolypocladium inflatum (NRRL 8044) ) was at first identified as Trichoderma polysporum (Link ex Pers) Rifai. The use of this strain for the production of antibiotic substances is described in Finnish Patent No. 54606. Growth conditions and taxonomy of this production strain are provided in Dreyfuss et al., Eur.
J. Appl. Microbiol. 3 :125 (1976) .
Other cyclosporin producing strains are described in Finnish Patent No . 52851 ( Cylindrocarpon lucidum Booth (NRRL 5760) ), German patent 298276 (Tolypocladium inflatum strain SF 136), Great Britain patent 2,227,489 (Tolypocladium varium), Japan patent 826 3093 (two strains of cyclosporin producing Fusarium), and US patent No . 5,409,816 (Tolypocladium sp . LEA3) . However, not all strains of Tolypocladium species are cyclosporin producing. Isaac et al.
( 1 9 9 0 ) .
Cyclosporin production varies among species and strains, and production processes for cyclosporin A
have encountered problems with low yields or the need for long fermentation times. Even where a microbial strain has been shown to produce relatively high yields of cyclosporin, the relative amount of cyclosporin produced often is small. Dexiu et al., Folia Microbiol. 36: 549-556 (1991) . The cyclosporin production of some known strains of Tolypocladium are compared in Isaac et al., Antimicro. Agents Chemother.
34: 121 (1990) . Of the nine cyclosporin producing strains compared in Isaacs et al., total cyclosporin production (forms A, B and C) after 10-15 days of CA 022~72~4 1998-12-04 W097/46580 PCT~B97/00654 growth ranged from 12 mg/liter to 123 mg/liter, using their described production process. A mutant of T.
inflatum NRRL 8044 is described as producing about 500 mg of Cyclosporin A per liter in Traber et al., J.
Antibiotics 42:591 (1989). Slight improvements in yield have been reported using selected amino acids or carbon sources, however, the operating expense of such methods renders them unsuitable for large-scale commercial use. See, e. g., Agathos et al., Ann. NY
Acad. Sci . 506:657 (1987); Kobel et al. Europ. J. Appl .
Microbiol. Biotechnol . 14:237 (1982). Accordingly, it is desirable to identify new strains of cyclosporin-producing microbes which can be used efficiently in the production of cyclosporins.
Sllmm;~ry of the Invention It is an object of the present invention to provide a productive cyclosporin-producing microbe.
It is a further object of the present invention to provide a biologically pure culture of a productive cyclosporin-producing microbe having the identifying characteristics of the deposit having provisional accession number I-1714, made in accordance with the provisions of the Budapest Treaty on 28 May 1996, with the Collection Nationale de Cultures de Microorganisms, Institut Pasteur, 25 Rue du Docteur Roux, Paris.
Another object of the present invention is a process for producing cyclosporin, wherein a microbe strain having all of the identifying characteristics of the deposit having provisional accession number I-1714 (Collection Nationale de Cultures de Microorganisms, Institut Pasteur, Paris) and referred to herein as Tolypocladium sp. (Poli), is aerobically fermented in a nutrient medium containing a carbon source utilizable by the microbe strain until cyclosporin is produced, and the cyclosporin produced is recovered.
CA 022~72~4 1998-12-04 W097/46580 PCT~B97/00654 The foregoing and other objects and aspects of the present invention are explained in detail in the specification set forth below.
Brief Description of the Drawings FIGURE lA is a photograph of a colony of one strain of Tolypocladium sp. (Poli).
FIGURE lB is a photograph showing the morphology of a strain of Tolypocladium sp. (Poli).
FIGURE 2A is a photograph of a colony of Tolypocladium inflatum ATCC 34921 (NRRL 8044).
FIGURE 2B is a photograph showing the microscopic morphology of Tolypocladium 7 nflatum ATCC
34921 (NRRL 8044).
FIGURE 3A is a chromatograph showing the production of cyclosporin by fermentation of Tolypocladium sp (Poli).
FIGURE 3B is a chart tabulating the data represented in the chromatograph of Figure 3A.
FIGURE 4A is a chromatograph showing the production of cyclosporin by fermentation of Tolypocladium sp NRRL 8044 (ATCC 34921).
FIGURE 4B is a chart tabulating the data represented in the chromatograph of Figure 4A.
Detailed Description of the Invention The novel microbe described herein provides a high yield of cyclosporin within a relatively short fermentation time, and is referred to herein as Tolypocladium sp. (Poli). This novel microbe was isolated from a soil sample obtained in Russia. The original isolate initially obtained from the soil sample possessed the general characteristics of the fungal genus Tolypocladium (as described in Gams, Persoonia 6:185 (1971) and Bissett, Can. J. Bot.
61:1311 (1983)): short cylindrical conidiophores with terminal and lateral phialides, ellipsoidal to CA 022~72~4 l998-l2-04 W097/46580 PCT~B97/00654 subglobose basally and narrowing into a cylindrical neck, often crooked, and bearing subglobose conidia.
This original strain produced a low yield of cyclosporin antibiotic complex. After repeated mutagenesis and selection a new microbial strain was isolated with a distinct macroscopic appearance of the colonies and distinct biochemical characteristics.
This strain is termed Tolypocladium sp. (Poli), and pure cultures have been grown. Specimens of Tolypocladium sp. (Poli~ have been deposited on 28 May 1996 according to the Budapest Treaty at the Collection Nationale de Cultures de Microorganismes, Institute Pasteur, 25 Rue du Docteur Roux, Paris, France (accession number I-1714).
The novel microbe described herein is - referred to as Tolypocladium sp. (Poli) and, while not wishing to be limited to a single theory of taxonomy, the data suggest that this microbe is a novel species of Tolypocladium. The novel microbe of the present invention possesses all of the general characteristics of the genus Tolypocladium yet is distinct from Tolypocladium inflatum (Gams) in morphology and in cyclosporin production. Alternatively, the novel microbe of the present invention may be termed a distinct strain of Tolypocladium inflatum.
Tolypocladium sp. Poli was compared to various species and strains of cyclosporin-producing microbes to establish its distinct characteristics.
Tolypocladium sp. (Poli) is slow-growing, forming cream colored colonies from 3-8 mm in diameter, with a wrinkled appearance when grown for 15 days at 24~C on a solid medium containing Beet molasses (1.5~), glycerol (1.5~), peptone (0.6~), sodium chloride (0.5~) and other mineral salts and trace elements. The vegetative hyphae are composed of chains of swollen cells, and spore-forming ability is weak. Conidiophores are hyaline, cylindrical, usually arising as short, CA 022~72~4 l998-l2-04 irregular branches from the aerial mycelium. Phialides are solitary or in verticils, ellipsoidal to subglobose basally, and narrowing abruptly into a cylindrical neck of variable length. The phialides become elongated toward the end of their development.
Tolypocladium sp. (Poli) can efficiently utilize the following as carbon sources: cellobiose, maltose, trehalose, galactose, glycerol, melezitose, sucrose, sorbitol, D-xylose, dextrin, and fructose.
The following can also be utilized as carbon sources by Tolypocladium sp. (Poli), although less efficiently:
mannitol and glucosamine. None of the following are utilized by Tolypocladium sp. (Poli) as a carbon source: L-arabinose, inositol, lactose, raffinose, xylitol, lactulose, stachyose, D-tagatose.
Tolypocladium sp. (Poli) can utilize either organic or inorganic nitrogen sources, including but not limited to corn steep liquor; dry yeast; protein hydrolysates (peptones) derived from casein, liver, lactalbumen, yeast, blood, meat and soya; vegetable meals (soya bean, cotton seed, corn gluten); urea and ammonium salts (nitrates, phosphates, sulphates).
Tolypocladium sp. (Poli) may be cultivated on various nutrient media containing the typical nutrients for fungi, including a carbon source suitable for (i.e., utilizable by) the microbe, a nitrogen source, and mineral salts and trace elements as are known in the art. As used herein, a medium capable of supporting Tolypocladium sp. (Poli) is one which contains a carbon source utilizable by the microbe and a nitrogen source utilizable by the microbe. Such a medium may be natural, synthetic or semisynthetic.
Numerous compositions useful as carbon sources and nitrogen sources in culture media are well known in the art. In addition, inorganic salts may be added to the culture medium as necessary, as is known in the art.
CA 022~72~4 l998-l2-04 W097/46580 PCT~B97/006~4 In a process according to the present invention for the production of cyclosporins, and particularly cyclosporin A, Tolypocladium sp. (Poli) is first cultured aerobically for 48-72 hours in a growth medium containing carbon and nitrogen sources utilizable by Tolypocladium sp . ( Poli) at temperatures from about 20~C to about 30~C, preferably at about 24-25~C. The growth medium is inoculated with a suspension of conidia and/or mycelia from Tolypocladium sp. (Poli). A fraction of this initial culture, such as 10-20~, is then used to inoculate a production medium containing carbon and nitrogen sources utilizable by the mlcrobe. Precursor amino acids may be added to the medium in order to improve the production of cyclosporin or to vary the relative amounts of the different cyclosporins, as is known in the art and as would be apparent to one skilled in the art. Aerobic fermentation is carried out at temperatures of from about 20~C to about 25~C
(preferably at about 24 ~C) for times of from about 8 to about 11 days. Commercially available fermentation devices may be used in the present process, as would be apparent to one of ordinary skill in the art.
Cyclosporin production may be monitored using methods known in the art including, for example, measurement of antifungal activity of the culture broth or chromatographic analysis. Fermentation is stopped when a maximum or desired cyclosporin production is obtained. The desired cyclosporins are then recovered from the culture broth using methods known in the art and purified as needed. See, e.g., US Patent No.
4,215,199; US Patent No. 5,156,960.
Use of the novel microbe of the present invention, here termed Tolypocladium sp. (Poli), according to the present invention provides a high yield of cyclosporin antibiotic complex. Yields of up to 1.5 g/L, 2.0 g/L, and even 3.0 g/L and above may be CA 022~72~4 l998-l2-04 ~VO 97/46580 PCT/IB97/00654 obtained. The cyclosporin produced by Tolypocladium sp. (Poli) contains cyclosporin A as the main product (more than 50~), and contains cyclosporins B, C and D
as minor components. Up to 60~, 70~ and even 80~ or more of cyclosporin A may be obtained. The relative amounts of the different cyclosporins may be varied somewhat by maintaining the pH of the culture at different values between pH 3 - pH 7, such as by adding a diluted ammonia solution (as would be apparent to one skilled in the art).
An advantageous cyclosporin producing process is described in the co-pending United States patent application of B. Bocchiola, V. Buran and A. Magni, filed concurrently herewith.
The following examples are provided to illustrate the present invention, and should not be construed as limiting thereof. In these examples, g means gram, L means liter, mL means milliLiter, rpm means revolutions per minute, WM means volume of air per unit volume of fermentation broth per minute, ~C
means degrees centigrade, and mcg means microgram.
Carbon Sources The ability of Tolypocladium inflatum ATCC
34921 (NRRL 8044) and Tolypocladium sp. (Poli) to utilize varied carbon sources was directly compared by growing cultures under identical conditions. The ability of Tolypocladium sp. LEA3 (U.S. Patent No.
5,409,816) to utilize various carbon sources was obtained from published sources.
Tolypocladium inflatum ATCC 34g21 (NRRL 8044) and Tolypocladium sp. (Poli) strains were compared in side-by-side growth tests using a liquid semi-synthetic medium containing corn steep powder (1 g/L), urea (1 g/L) and mineral salts (2 g/L KH2PO4; 3 g/L NaCl; 0.5 g/L MgSO4; 1 g/L NaNO3; 0.5 g/L KCl; 0.015 g/L FeSO4;
CA 022~72~4 1998-12-04 0.003 g/L MnSO4; 0.003 ZnSO4; 0.001 CuS04), with different carbon sources added to a final concentration of 30 g/L. Shake flasks containing 25 mL of medium were inoculated with a suspension of conidia and mycelia and incubated for 4 days at 24~C on a gyratory shaker at 240 rpm. Growth was assessed by measuring the dry weight in each flask after 4 days, compared with a control flask containing the same medium without a carbon source, inoculated with the same suspension.
Information provided in Table 1 regarding Tolypocladium sp. LEA3 was obtained from U.S. Patent No. 5,409,816.
As shown in Table 1, Tolypocladium sp. (Poli) was unable to use L-arabinose, inositol, and xylitol, whereas Tolypocladium sp. LEA3 was able to utilize each of these compounds as a carbon source. In contrast to T. inflatum ATCC 34921 (NRRL 8044), T. (Poli) was unable to use inositol or xylitol as a carbon source.
CA 022~72~4 1998-12-04 Carbon To1ypoc1adiumTo1ypoc1adium T. inf1atum Source sp. (LEA3)sp. (Poli) ATCC 34921 (NRRL 8044) Control L-arabinose + - -Cellobiose + + +
Inositol + +
Lactose Maltose + + +
Rafflnose Trehalose + + +
Xylitol + - +
Galactose + + +
Glycerol + + +
Melezitose + + +
Sucrose + + +
Sorbitol + + +
D-Xylose + + +
Dextrin (nd) + +
Fructose (nd) + +
Mannitol (nd) +/- +
Glucosamine (nd) +/- +/
Lactulose (nd) Stachyose (nd) - (nd) 2 5 D-tagatose (nd) - (nd) (-) indicates a dry weight of < 1 g, (+l-) indicates a dry weight of bet~ -en 1 and 2 g/L
(+) indicates a dry weight of ~ 2 g/~
(nd) indicates this test was not done CA 022~72~4 l998-l2-04 W097/46580 PCTnB97/00654 ComParison of ColonY Growth and Funqal MorPholo~y The growth and characteristics of colonies of Tolypocladium sp. (LEA3), Tolypocladium inflatum ATCC
34921 (NRRL 8044), and Tolypocladium sp. (Poli) were compared, as was fungal morphology.
Fungal morphology of Tolypocladium inflatum ATCC 34921 (NRRL 8044) and Tolypocladium sp. (Poli) were compared after growth under identical conditions:
microbes were grown directly on a sterile microscope slide, partially submerged in a liquid medium containing glucose (1.5~), glycerol (3~), yeast extract (0.5~), KH2P04 (0.5~) and NaCl (0.5~) at room temperature. After 5 and 10 days the aerial mycelium were observed using a microscope. Description of Tolypocladium sp. (LEA3) was obtained from the published literature. Results are provided in Table 3.
Table 2 compares additional characteristics of the three microbe strains. Tolypocladium sp. (Poli) can be distinguished from each of the other two strains as shown, for example, by comparing colony appearance, the forms of cyclosporin produced, and morphology.
Growth was assessed subjectively using visual inspection and measurement. Colonies of Tolypocladium inflatum ATCC 34921 (NRRL 8044), when grown on a solid medium, are visible after 4-5 days while colonies of Tolypocladium sp. (Poli) are visible after one week.
When these two microbial strains are grown in the same conditions using a liquid medium containing a suitable carbon source and identical inoculum, the growth curve obtained by plotting the dry weight values at different times are different, with Tolypocladium inflatum ATCC
34921 (NRRL 8044) growing faster than Tolypocladium sp.
(Poli).
U~
o. ~ ~ ~ Q
~ ~ s a) ~ ,,~ U~
~ ~ 3~ ~ 3 ~~ ~ U~
O -~1 U.
V -~ U~
~ ~ ~ ~ u. Q
o ~ ~ ~ --- U
O ~ ~ cn a~
U~
~n a -,~ tn D~
ta -~ 3 ~, v s Q d~ u 3 4~ 3 ~ U~
au ~ o ~ u~
~ -- u~
E- - u~ '-3 U~
a) ~ o v Q~ ~ 3 3~ U~ O
(~) C O t~ P.
~ ~ O O
U~ ~.,~ p.l .C- C~ ~ ~ ~
o C~ O ~ r O
~cn ~ ~~ C
~, C Cl: ~ O
n o r~
3 ~O = Id 3 Q O ~ 3 C~ ~ V.~ ~ ~ D ~
'' Ul .1 C
~ O
c- ~ ~ Q ~1 0 (d Z ~ -~ O
'c U
o ~ ~
o o o cQ c= ~
O O O
:~ ~ ~ Q~
c_ ._Q ~Q =i O 1~ 0 aJ O
_ ~ Q ~ Q
>, >
~n ~ Q a) (/) 1/l Q a) o ~ v O O C_ Q C ~ 0 ~0 ~ O Q ~ ~) O ~ a) o c Q ~ s a~~_0 C~-~ c--~ a ~7 0 ~ ~r) 3 ~ ~ ~ t~ ~ ~) ~ a, ~ Q ~ O cO ~ ai o ~ EQ ~ ~ cO ~ a~ 3 ~ ~Q
c~ O ' ~ Q ~ O ' s~ O
~, >, a) O ~ ~ ~c_ ~ >
-- O >~ ~ C ~ ~ _ O >, (1 r~ ~ 'C-- ~~ O ' V ' ~ ~ ~ O ~= ~ ~
5~ 0 = ~ ~ ~ ~ r~--~ O = ,a CL V) ~ s~ ~ 3 ~ ~ ~ ~ 3 >, a~ a S s O ~ E ~ E
s (~ O _ (~ ' O s 0 ~1 cn E ~ ~n E
ca) ~ ~ ~ a, ~ '~
a) ~ u, S ~_ tn s ~ cl) o ~ c ~ ~ _ ~ c ~ a~
Q ~ ' E ~~ ' E
o a) ~,Q ~a) >~Q -- v~
~C_ ~ C .~ Vl ~--_ ~ ~ ~J~
~~ --' O -- ' ~ ~ O -- -- ~
o>, cr~ s a~ cJ s a) c_ o ~ ~ ,_ '~_ ~ '~ ~J
C ~ ~j= Q
~ C~ r_ o .... . _ _, .. .
CA 022~72~4 l998-l2-04 W097/46580 PCT~B97/00654 A colony of one strain of Tolypocladium sp.
(Poli) is shown in Figure lA; a colony of Tolypocladium inflatum ATCC 34921 (NRRL 8044) is shown in Figure 2A
for comparison. Figure lB is a photograph showing the morphology of a strain of Tolypocladlum sp. (Poli);
Figure 2b is a photograph showing the microscopic morphology of Tolypocladium inflatum ATCC 34921 (NRRL
8044).
EX~iMPLE 3 C~closPorin Production bY TolYpocladium sp. (Poli) Tolypocladium sp (Poli), as described above, was cultured and the production of cyclosporin was assessed. The microbe was cultured using a seed medium containing sucrose and a production medium containing glucose was utilized. Cyclosporin A was separated from other forms of cyclosporin and other fermentation byproducts using chromatography. Using identical methods, Tolypocladium sp NRRL 8044 (ATCC 34921) was cultured and the production of cyclosporin was assessed. Growth and fermentation were carried out as follows: A shake flask of 2000 mL capacity was filled with 500 mL of a seed medium containing 2 sucrose, 1.5~ glycerol, 0.7~ ammonium sulfate, 0.5~
sodium chloride and 0.2~ potassium phosphate. Flasks were inoculated with a suspension of mycelium and conidia obtained from a piece of a 14-20 day old agar slant culture, chopped in 6-10 mL of water. Flasks were incubated for 2-3 days at 20~C to 30~C (preferably at 24~C) on an alternative shaker. Flasks were then used to inoculate a fermentor of 10 L capacity, filled with 5 L of the same seed medium. The seed culture was cultivated for 2-3 days at 20~C to 30~C (preferably at 24~C), and used as inoculum for the production medium (composed of glucose, glycerol, peptone, urea, sodium nitrate, ammonium sulfate, potassium phosphate, and other mineral salts and trace elements as are known in CA 022~72~4 l998-l2-04 W097/46580 PCT~B97/00654 the art). In a convenient method, a 10~ to 20~ v/v of the seed culture was transferred in the production medium. Fermentation was performed at 20~C to 25~C
(preferably at 24~C) for 10-14 days. The aerobic conditions were maintained by stirring (60 to 120 rpm) and aerating the broth at 0.5 to 1 VVM (volume of air per unit volume of fermentation broth per minute).
The cyclosporin concentration of broth was 7measured by High Performance Liquid Chromatography (HPLC) and the fermentation was stopped when cyclosporin production reached a maximum. The results of HPLC for Tolypocladium sp (Poli) are provided in Figures 3A and 3~; that for Tolypocladium sp NRRL 8044 (ATCC 34921) is provided in Figures 4A and 4B.
As shown by the HPLC results, the cyclosporin A overall yield using Tolypocladium sp ( Poli) was more than 2 g/liter. The cyclosporin A overall yield using Tolypocladium sp NRRL 8044 (ATCC 34921) was less than 0.5 g/liter. In published reports, fermentation of 20 Tolypocladium sp. LEA3 is stated as producing up to 1.5 g/l of cyclosporin A after six days of fermentation, with the relative proportion of cyclosporin A up to 84 (US Patent No. 5,409,816).
The foregoing is illustrative of the present invention and is not to be construed as limiting thereof. The invention is defined by the following claims, with equivalents of the claims to be included therein.
Field of the In~ention The present invention relates to a novel cyclosporin-producing microbe, apparently a member of the fungal genus Tolypocladium, and to a process for producing cyclosporins by the fermentation of this microbe.
Back~round of the In~ention Cyclosporins are a group o~ non-polar cyclic oligopeptide compounds having immunosuppressant activity. Cyclosporins are produced by fungal fermentation. Cyclosporins have been employed for several years to combat rejection of transplanted organs and tissues in humans. Recently, investigators have been seeking additional therapeutic applications for the drug.
At least nine different cyclosporins are produced by the fungi, including cyclosporin A, B, C, D, E, F, G, H, and I, all having varying amino acid composition. Cyclosporin A is the major component and currently enjoys the most wide-spread clinical use.
See, e.g., Ruegger et al., Helv. Chim. Acta 59:1075 (1976); Traber et al., Helv. Chim. Acta 60:1568 (1977);
Rehacek and De-xiu, Process Biochem 26:157 (1991).
Cyclosporin A is commercially available under the tradename SANDIMMUNE~ from Sandoz Corp.
Cyclosporins were originally isolated as - metabolites produced by fungal strains of Cylindrocarpon lucidum Booth and Tolypocladium inflatum ~ Gams (Gams, Persoonia 6:185 (1971)), isolated from soil samples from the United States of America and Norway.
T. inflatum is also known as Tolypocladium niveum.
Isaac et al., Antimicro. Agents Chemother. 34:121 - CONFIRM~ION COPY
CA 022~72~4 1998-12-04 W097/46580 PCTnB97/00654 (1990). (The genus Tolypocladium was first described by Gams, Persoonia, 6 :185 (1971); the genus name Beauveria has been used synonymously with Tolypocladium.) Species of Tolypocladium are typically slow in growth and form white, flocculent colonies with a large amount of spores.
A production strain of Tolypocladium (Tolypocladium inflatum (NRRL 8044) ) was at first identified as Trichoderma polysporum (Link ex Pers) Rifai. The use of this strain for the production of antibiotic substances is described in Finnish Patent No. 54606. Growth conditions and taxonomy of this production strain are provided in Dreyfuss et al., Eur.
J. Appl. Microbiol. 3 :125 (1976) .
Other cyclosporin producing strains are described in Finnish Patent No . 52851 ( Cylindrocarpon lucidum Booth (NRRL 5760) ), German patent 298276 (Tolypocladium inflatum strain SF 136), Great Britain patent 2,227,489 (Tolypocladium varium), Japan patent 826 3093 (two strains of cyclosporin producing Fusarium), and US patent No . 5,409,816 (Tolypocladium sp . LEA3) . However, not all strains of Tolypocladium species are cyclosporin producing. Isaac et al.
( 1 9 9 0 ) .
Cyclosporin production varies among species and strains, and production processes for cyclosporin A
have encountered problems with low yields or the need for long fermentation times. Even where a microbial strain has been shown to produce relatively high yields of cyclosporin, the relative amount of cyclosporin produced often is small. Dexiu et al., Folia Microbiol. 36: 549-556 (1991) . The cyclosporin production of some known strains of Tolypocladium are compared in Isaac et al., Antimicro. Agents Chemother.
34: 121 (1990) . Of the nine cyclosporin producing strains compared in Isaacs et al., total cyclosporin production (forms A, B and C) after 10-15 days of CA 022~72~4 1998-12-04 W097/46580 PCT~B97/00654 growth ranged from 12 mg/liter to 123 mg/liter, using their described production process. A mutant of T.
inflatum NRRL 8044 is described as producing about 500 mg of Cyclosporin A per liter in Traber et al., J.
Antibiotics 42:591 (1989). Slight improvements in yield have been reported using selected amino acids or carbon sources, however, the operating expense of such methods renders them unsuitable for large-scale commercial use. See, e. g., Agathos et al., Ann. NY
Acad. Sci . 506:657 (1987); Kobel et al. Europ. J. Appl .
Microbiol. Biotechnol . 14:237 (1982). Accordingly, it is desirable to identify new strains of cyclosporin-producing microbes which can be used efficiently in the production of cyclosporins.
Sllmm;~ry of the Invention It is an object of the present invention to provide a productive cyclosporin-producing microbe.
It is a further object of the present invention to provide a biologically pure culture of a productive cyclosporin-producing microbe having the identifying characteristics of the deposit having provisional accession number I-1714, made in accordance with the provisions of the Budapest Treaty on 28 May 1996, with the Collection Nationale de Cultures de Microorganisms, Institut Pasteur, 25 Rue du Docteur Roux, Paris.
Another object of the present invention is a process for producing cyclosporin, wherein a microbe strain having all of the identifying characteristics of the deposit having provisional accession number I-1714 (Collection Nationale de Cultures de Microorganisms, Institut Pasteur, Paris) and referred to herein as Tolypocladium sp. (Poli), is aerobically fermented in a nutrient medium containing a carbon source utilizable by the microbe strain until cyclosporin is produced, and the cyclosporin produced is recovered.
CA 022~72~4 1998-12-04 W097/46580 PCT~B97/00654 The foregoing and other objects and aspects of the present invention are explained in detail in the specification set forth below.
Brief Description of the Drawings FIGURE lA is a photograph of a colony of one strain of Tolypocladium sp. (Poli).
FIGURE lB is a photograph showing the morphology of a strain of Tolypocladium sp. (Poli).
FIGURE 2A is a photograph of a colony of Tolypocladium inflatum ATCC 34921 (NRRL 8044).
FIGURE 2B is a photograph showing the microscopic morphology of Tolypocladium 7 nflatum ATCC
34921 (NRRL 8044).
FIGURE 3A is a chromatograph showing the production of cyclosporin by fermentation of Tolypocladium sp (Poli).
FIGURE 3B is a chart tabulating the data represented in the chromatograph of Figure 3A.
FIGURE 4A is a chromatograph showing the production of cyclosporin by fermentation of Tolypocladium sp NRRL 8044 (ATCC 34921).
FIGURE 4B is a chart tabulating the data represented in the chromatograph of Figure 4A.
Detailed Description of the Invention The novel microbe described herein provides a high yield of cyclosporin within a relatively short fermentation time, and is referred to herein as Tolypocladium sp. (Poli). This novel microbe was isolated from a soil sample obtained in Russia. The original isolate initially obtained from the soil sample possessed the general characteristics of the fungal genus Tolypocladium (as described in Gams, Persoonia 6:185 (1971) and Bissett, Can. J. Bot.
61:1311 (1983)): short cylindrical conidiophores with terminal and lateral phialides, ellipsoidal to CA 022~72~4 l998-l2-04 W097/46580 PCT~B97/00654 subglobose basally and narrowing into a cylindrical neck, often crooked, and bearing subglobose conidia.
This original strain produced a low yield of cyclosporin antibiotic complex. After repeated mutagenesis and selection a new microbial strain was isolated with a distinct macroscopic appearance of the colonies and distinct biochemical characteristics.
This strain is termed Tolypocladium sp. (Poli), and pure cultures have been grown. Specimens of Tolypocladium sp. (Poli~ have been deposited on 28 May 1996 according to the Budapest Treaty at the Collection Nationale de Cultures de Microorganismes, Institute Pasteur, 25 Rue du Docteur Roux, Paris, France (accession number I-1714).
The novel microbe described herein is - referred to as Tolypocladium sp. (Poli) and, while not wishing to be limited to a single theory of taxonomy, the data suggest that this microbe is a novel species of Tolypocladium. The novel microbe of the present invention possesses all of the general characteristics of the genus Tolypocladium yet is distinct from Tolypocladium inflatum (Gams) in morphology and in cyclosporin production. Alternatively, the novel microbe of the present invention may be termed a distinct strain of Tolypocladium inflatum.
Tolypocladium sp. Poli was compared to various species and strains of cyclosporin-producing microbes to establish its distinct characteristics.
Tolypocladium sp. (Poli) is slow-growing, forming cream colored colonies from 3-8 mm in diameter, with a wrinkled appearance when grown for 15 days at 24~C on a solid medium containing Beet molasses (1.5~), glycerol (1.5~), peptone (0.6~), sodium chloride (0.5~) and other mineral salts and trace elements. The vegetative hyphae are composed of chains of swollen cells, and spore-forming ability is weak. Conidiophores are hyaline, cylindrical, usually arising as short, CA 022~72~4 l998-l2-04 irregular branches from the aerial mycelium. Phialides are solitary or in verticils, ellipsoidal to subglobose basally, and narrowing abruptly into a cylindrical neck of variable length. The phialides become elongated toward the end of their development.
Tolypocladium sp. (Poli) can efficiently utilize the following as carbon sources: cellobiose, maltose, trehalose, galactose, glycerol, melezitose, sucrose, sorbitol, D-xylose, dextrin, and fructose.
The following can also be utilized as carbon sources by Tolypocladium sp. (Poli), although less efficiently:
mannitol and glucosamine. None of the following are utilized by Tolypocladium sp. (Poli) as a carbon source: L-arabinose, inositol, lactose, raffinose, xylitol, lactulose, stachyose, D-tagatose.
Tolypocladium sp. (Poli) can utilize either organic or inorganic nitrogen sources, including but not limited to corn steep liquor; dry yeast; protein hydrolysates (peptones) derived from casein, liver, lactalbumen, yeast, blood, meat and soya; vegetable meals (soya bean, cotton seed, corn gluten); urea and ammonium salts (nitrates, phosphates, sulphates).
Tolypocladium sp. (Poli) may be cultivated on various nutrient media containing the typical nutrients for fungi, including a carbon source suitable for (i.e., utilizable by) the microbe, a nitrogen source, and mineral salts and trace elements as are known in the art. As used herein, a medium capable of supporting Tolypocladium sp. (Poli) is one which contains a carbon source utilizable by the microbe and a nitrogen source utilizable by the microbe. Such a medium may be natural, synthetic or semisynthetic.
Numerous compositions useful as carbon sources and nitrogen sources in culture media are well known in the art. In addition, inorganic salts may be added to the culture medium as necessary, as is known in the art.
CA 022~72~4 l998-l2-04 W097/46580 PCT~B97/006~4 In a process according to the present invention for the production of cyclosporins, and particularly cyclosporin A, Tolypocladium sp. (Poli) is first cultured aerobically for 48-72 hours in a growth medium containing carbon and nitrogen sources utilizable by Tolypocladium sp . ( Poli) at temperatures from about 20~C to about 30~C, preferably at about 24-25~C. The growth medium is inoculated with a suspension of conidia and/or mycelia from Tolypocladium sp. (Poli). A fraction of this initial culture, such as 10-20~, is then used to inoculate a production medium containing carbon and nitrogen sources utilizable by the mlcrobe. Precursor amino acids may be added to the medium in order to improve the production of cyclosporin or to vary the relative amounts of the different cyclosporins, as is known in the art and as would be apparent to one skilled in the art. Aerobic fermentation is carried out at temperatures of from about 20~C to about 25~C
(preferably at about 24 ~C) for times of from about 8 to about 11 days. Commercially available fermentation devices may be used in the present process, as would be apparent to one of ordinary skill in the art.
Cyclosporin production may be monitored using methods known in the art including, for example, measurement of antifungal activity of the culture broth or chromatographic analysis. Fermentation is stopped when a maximum or desired cyclosporin production is obtained. The desired cyclosporins are then recovered from the culture broth using methods known in the art and purified as needed. See, e.g., US Patent No.
4,215,199; US Patent No. 5,156,960.
Use of the novel microbe of the present invention, here termed Tolypocladium sp. (Poli), according to the present invention provides a high yield of cyclosporin antibiotic complex. Yields of up to 1.5 g/L, 2.0 g/L, and even 3.0 g/L and above may be CA 022~72~4 l998-l2-04 ~VO 97/46580 PCT/IB97/00654 obtained. The cyclosporin produced by Tolypocladium sp. (Poli) contains cyclosporin A as the main product (more than 50~), and contains cyclosporins B, C and D
as minor components. Up to 60~, 70~ and even 80~ or more of cyclosporin A may be obtained. The relative amounts of the different cyclosporins may be varied somewhat by maintaining the pH of the culture at different values between pH 3 - pH 7, such as by adding a diluted ammonia solution (as would be apparent to one skilled in the art).
An advantageous cyclosporin producing process is described in the co-pending United States patent application of B. Bocchiola, V. Buran and A. Magni, filed concurrently herewith.
The following examples are provided to illustrate the present invention, and should not be construed as limiting thereof. In these examples, g means gram, L means liter, mL means milliLiter, rpm means revolutions per minute, WM means volume of air per unit volume of fermentation broth per minute, ~C
means degrees centigrade, and mcg means microgram.
Carbon Sources The ability of Tolypocladium inflatum ATCC
34921 (NRRL 8044) and Tolypocladium sp. (Poli) to utilize varied carbon sources was directly compared by growing cultures under identical conditions. The ability of Tolypocladium sp. LEA3 (U.S. Patent No.
5,409,816) to utilize various carbon sources was obtained from published sources.
Tolypocladium inflatum ATCC 34g21 (NRRL 8044) and Tolypocladium sp. (Poli) strains were compared in side-by-side growth tests using a liquid semi-synthetic medium containing corn steep powder (1 g/L), urea (1 g/L) and mineral salts (2 g/L KH2PO4; 3 g/L NaCl; 0.5 g/L MgSO4; 1 g/L NaNO3; 0.5 g/L KCl; 0.015 g/L FeSO4;
CA 022~72~4 1998-12-04 0.003 g/L MnSO4; 0.003 ZnSO4; 0.001 CuS04), with different carbon sources added to a final concentration of 30 g/L. Shake flasks containing 25 mL of medium were inoculated with a suspension of conidia and mycelia and incubated for 4 days at 24~C on a gyratory shaker at 240 rpm. Growth was assessed by measuring the dry weight in each flask after 4 days, compared with a control flask containing the same medium without a carbon source, inoculated with the same suspension.
Information provided in Table 1 regarding Tolypocladium sp. LEA3 was obtained from U.S. Patent No. 5,409,816.
As shown in Table 1, Tolypocladium sp. (Poli) was unable to use L-arabinose, inositol, and xylitol, whereas Tolypocladium sp. LEA3 was able to utilize each of these compounds as a carbon source. In contrast to T. inflatum ATCC 34921 (NRRL 8044), T. (Poli) was unable to use inositol or xylitol as a carbon source.
CA 022~72~4 1998-12-04 Carbon To1ypoc1adiumTo1ypoc1adium T. inf1atum Source sp. (LEA3)sp. (Poli) ATCC 34921 (NRRL 8044) Control L-arabinose + - -Cellobiose + + +
Inositol + +
Lactose Maltose + + +
Rafflnose Trehalose + + +
Xylitol + - +
Galactose + + +
Glycerol + + +
Melezitose + + +
Sucrose + + +
Sorbitol + + +
D-Xylose + + +
Dextrin (nd) + +
Fructose (nd) + +
Mannitol (nd) +/- +
Glucosamine (nd) +/- +/
Lactulose (nd) Stachyose (nd) - (nd) 2 5 D-tagatose (nd) - (nd) (-) indicates a dry weight of < 1 g, (+l-) indicates a dry weight of bet~ -en 1 and 2 g/L
(+) indicates a dry weight of ~ 2 g/~
(nd) indicates this test was not done CA 022~72~4 l998-l2-04 W097/46580 PCTnB97/00654 ComParison of ColonY Growth and Funqal MorPholo~y The growth and characteristics of colonies of Tolypocladium sp. (LEA3), Tolypocladium inflatum ATCC
34921 (NRRL 8044), and Tolypocladium sp. (Poli) were compared, as was fungal morphology.
Fungal morphology of Tolypocladium inflatum ATCC 34921 (NRRL 8044) and Tolypocladium sp. (Poli) were compared after growth under identical conditions:
microbes were grown directly on a sterile microscope slide, partially submerged in a liquid medium containing glucose (1.5~), glycerol (3~), yeast extract (0.5~), KH2P04 (0.5~) and NaCl (0.5~) at room temperature. After 5 and 10 days the aerial mycelium were observed using a microscope. Description of Tolypocladium sp. (LEA3) was obtained from the published literature. Results are provided in Table 3.
Table 2 compares additional characteristics of the three microbe strains. Tolypocladium sp. (Poli) can be distinguished from each of the other two strains as shown, for example, by comparing colony appearance, the forms of cyclosporin produced, and morphology.
Growth was assessed subjectively using visual inspection and measurement. Colonies of Tolypocladium inflatum ATCC 34921 (NRRL 8044), when grown on a solid medium, are visible after 4-5 days while colonies of Tolypocladium sp. (Poli) are visible after one week.
When these two microbial strains are grown in the same conditions using a liquid medium containing a suitable carbon source and identical inoculum, the growth curve obtained by plotting the dry weight values at different times are different, with Tolypocladium inflatum ATCC
34921 (NRRL 8044) growing faster than Tolypocladium sp.
(Poli).
U~
o. ~ ~ ~ Q
~ ~ s a) ~ ,,~ U~
~ ~ 3~ ~ 3 ~~ ~ U~
O -~1 U.
V -~ U~
~ ~ ~ ~ u. Q
o ~ ~ ~ --- U
O ~ ~ cn a~
U~
~n a -,~ tn D~
ta -~ 3 ~, v s Q d~ u 3 4~ 3 ~ U~
au ~ o ~ u~
~ -- u~
E- - u~ '-3 U~
a) ~ o v Q~ ~ 3 3~ U~ O
(~) C O t~ P.
~ ~ O O
U~ ~.,~ p.l .C- C~ ~ ~ ~
o C~ O ~ r O
~cn ~ ~~ C
~, C Cl: ~ O
n o r~
3 ~O = Id 3 Q O ~ 3 C~ ~ V.~ ~ ~ D ~
'' Ul .1 C
~ O
c- ~ ~ Q ~1 0 (d Z ~ -~ O
'c U
o ~ ~
o o o cQ c= ~
O O O
:~ ~ ~ Q~
c_ ._Q ~Q =i O 1~ 0 aJ O
_ ~ Q ~ Q
>, >
~n ~ Q a) (/) 1/l Q a) o ~ v O O C_ Q C ~ 0 ~0 ~ O Q ~ ~) O ~ a) o c Q ~ s a~~_0 C~-~ c--~ a ~7 0 ~ ~r) 3 ~ ~ ~ t~ ~ ~) ~ a, ~ Q ~ O cO ~ ai o ~ EQ ~ ~ cO ~ a~ 3 ~ ~Q
c~ O ' ~ Q ~ O ' s~ O
~, >, a) O ~ ~ ~c_ ~ >
-- O >~ ~ C ~ ~ _ O >, (1 r~ ~ 'C-- ~~ O ' V ' ~ ~ ~ O ~= ~ ~
5~ 0 = ~ ~ ~ ~ r~--~ O = ,a CL V) ~ s~ ~ 3 ~ ~ ~ ~ 3 >, a~ a S s O ~ E ~ E
s (~ O _ (~ ' O s 0 ~1 cn E ~ ~n E
ca) ~ ~ ~ a, ~ '~
a) ~ u, S ~_ tn s ~ cl) o ~ c ~ ~ _ ~ c ~ a~
Q ~ ' E ~~ ' E
o a) ~,Q ~a) >~Q -- v~
~C_ ~ C .~ Vl ~--_ ~ ~ ~J~
~~ --' O -- ' ~ ~ O -- -- ~
o>, cr~ s a~ cJ s a) c_ o ~ ~ ,_ '~_ ~ '~ ~J
C ~ ~j= Q
~ C~ r_ o .... . _ _, .. .
CA 022~72~4 l998-l2-04 W097/46580 PCT~B97/00654 A colony of one strain of Tolypocladium sp.
(Poli) is shown in Figure lA; a colony of Tolypocladium inflatum ATCC 34921 (NRRL 8044) is shown in Figure 2A
for comparison. Figure lB is a photograph showing the morphology of a strain of Tolypocladlum sp. (Poli);
Figure 2b is a photograph showing the microscopic morphology of Tolypocladium inflatum ATCC 34921 (NRRL
8044).
EX~iMPLE 3 C~closPorin Production bY TolYpocladium sp. (Poli) Tolypocladium sp (Poli), as described above, was cultured and the production of cyclosporin was assessed. The microbe was cultured using a seed medium containing sucrose and a production medium containing glucose was utilized. Cyclosporin A was separated from other forms of cyclosporin and other fermentation byproducts using chromatography. Using identical methods, Tolypocladium sp NRRL 8044 (ATCC 34921) was cultured and the production of cyclosporin was assessed. Growth and fermentation were carried out as follows: A shake flask of 2000 mL capacity was filled with 500 mL of a seed medium containing 2 sucrose, 1.5~ glycerol, 0.7~ ammonium sulfate, 0.5~
sodium chloride and 0.2~ potassium phosphate. Flasks were inoculated with a suspension of mycelium and conidia obtained from a piece of a 14-20 day old agar slant culture, chopped in 6-10 mL of water. Flasks were incubated for 2-3 days at 20~C to 30~C (preferably at 24~C) on an alternative shaker. Flasks were then used to inoculate a fermentor of 10 L capacity, filled with 5 L of the same seed medium. The seed culture was cultivated for 2-3 days at 20~C to 30~C (preferably at 24~C), and used as inoculum for the production medium (composed of glucose, glycerol, peptone, urea, sodium nitrate, ammonium sulfate, potassium phosphate, and other mineral salts and trace elements as are known in CA 022~72~4 l998-l2-04 W097/46580 PCT~B97/00654 the art). In a convenient method, a 10~ to 20~ v/v of the seed culture was transferred in the production medium. Fermentation was performed at 20~C to 25~C
(preferably at 24~C) for 10-14 days. The aerobic conditions were maintained by stirring (60 to 120 rpm) and aerating the broth at 0.5 to 1 VVM (volume of air per unit volume of fermentation broth per minute).
The cyclosporin concentration of broth was 7measured by High Performance Liquid Chromatography (HPLC) and the fermentation was stopped when cyclosporin production reached a maximum. The results of HPLC for Tolypocladium sp (Poli) are provided in Figures 3A and 3~; that for Tolypocladium sp NRRL 8044 (ATCC 34921) is provided in Figures 4A and 4B.
As shown by the HPLC results, the cyclosporin A overall yield using Tolypocladium sp ( Poli) was more than 2 g/liter. The cyclosporin A overall yield using Tolypocladium sp NRRL 8044 (ATCC 34921) was less than 0.5 g/liter. In published reports, fermentation of 20 Tolypocladium sp. LEA3 is stated as producing up to 1.5 g/l of cyclosporin A after six days of fermentation, with the relative proportion of cyclosporin A up to 84 (US Patent No. 5,409,816).
The foregoing is illustrative of the present invention and is not to be construed as limiting thereof. The invention is defined by the following claims, with equivalents of the claims to be included therein.
Claims (6)
1. A biologically pure culture of the cyclosporin-producing microbe deposited as provisional accession number I-1714, Collection Nationale de Cultures de Microorganisms, Institut Pasteur.
2. A process for producing cyclosporin, comprising aerobically fermenting a microbe having all of the identifying characteristics of the microbe deposited as provisional accession number I-1714, Collection Nationale de Cultures de Microorganisms, Institut Pasteur, in a nutrient medium comprising a carbon source utilizable by said microbe, until cyclosporin is produced and recovering the cyclosporin produced.
.
.
3. The process according to claim 2 wherein the cyclosporin recovered is cyclosporin A.
4. The process according to claim 2 wherein said nutrient medium comprises a carbon source selected from the group consisting of cellobiose, maltose, trehalose, galactose, glycerol, melezitose, sucrose, sorbitol, D-xylose, dextrin, fructose, mannitol and glucosamine.
5. The process according to claim 2 wherein said nutrient medium comprises glucose, glycerol, peptone, and ammonium sulfate.
6. The process according to claim 2 wherein the nutrient medium contains urea in a concentration of from about 0.01% to about 3.0% weight/weight.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/658,653 US5747330A (en) | 1996-06-05 | 1996-06-05 | Antibiotic producing microbe |
| US08/658,653 | 1996-06-05 | ||
| PCT/IB1997/000654 WO1997046580A1 (en) | 1996-06-05 | 1997-06-05 | Antibiotic producing microbe |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2257254A1 CA2257254A1 (en) | 1997-12-11 |
| CA2257254C true CA2257254C (en) | 2002-08-13 |
Family
ID=24642117
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002257254A Expired - Fee Related CA2257254C (en) | 1996-06-05 | 1997-06-05 | Antibiotic producing microbe |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US5747330A (en) |
| EP (1) | EP0906336B1 (en) |
| AT (1) | ATE275153T1 (en) |
| AU (1) | AU2912297A (en) |
| CA (1) | CA2257254C (en) |
| DE (1) | DE69730497D1 (en) |
| ES (1) | ES2227693T3 (en) |
| WO (2) | WO1997046580A1 (en) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6176701B1 (en) * | 1997-10-01 | 2001-01-23 | Barnett Joel Robinson | Method for improving fuel efficiency in combustion chambers |
| US20030220234A1 (en) * | 1998-11-02 | 2003-11-27 | Selvaraj Naicker | Deuterated cyclosporine analogs and their use as immunodulating agents |
| EP0991660B8 (en) | 1997-10-08 | 2006-04-05 | Isotechnika,Inc. | DEUTERATED and undeuterated CYCLOSPORINE ANALOGS AND THEIR USE AS IMMUNOMODULATING AGENTS |
| NZ512599A (en) | 1998-12-30 | 2003-10-31 | Dexcel Ltd | Formulation for cyclosporin administration featuring a hydrophilic solvent and a surfactant with a HLB of less than 5 |
| US7732404B2 (en) * | 1999-12-30 | 2010-06-08 | Dexcel Ltd | Pro-nanodispersion for the delivery of cyclosporin |
| AU2000235743A1 (en) | 2000-02-29 | 2001-09-12 | Biocon India Limited | Manufacture and purification of cyclosporin a |
| US6547900B2 (en) | 2001-01-24 | 2003-04-15 | Breed Automotive Technology, Inc. | Method of stabilizing the density of gas generant pellets containing nitroguanidine |
| PL210795B1 (en) | 2001-10-19 | 2012-03-30 | Isotechnika Inc | The method of producing the ISATX247 enriched isomer (E), the method of producing the ISATX247 enriched mixture of the (Z) isomer, the method of stereoselective synthesis of the (E) ISATX247 isomer, the method of stereoselective synthesis of the (Z) isomer ISATX247 and the method of producing the mixture of ISATX247 isomers |
| KR101072121B1 (en) | 2008-02-19 | 2011-10-10 | (주)차바이오앤디오스텍 | Method for mass culture of cyclosporine at Tolypocladium niveum |
| EP2151450A1 (en) | 2008-07-29 | 2010-02-10 | Sandoz AG | Method for processing microbiologically produced cyclic oligopeptides |
| US10945443B2 (en) | 2017-09-29 | 2021-03-16 | Valent Biosciences Llc | Tolypocladium album strain |
| CN115125148A (en) * | 2021-03-24 | 2022-09-30 | 宁夏泰胜生物科技有限公司 | Culture medium and culture method for producing cyclosporine by fermentation of Sinkiang saururi |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4117118A (en) * | 1976-04-09 | 1978-09-26 | Sandoz Ltd. | Organic compounds |
| CH633826A5 (en) * | 1977-04-06 | 1982-12-31 | Sandoz Ag | Process for the preparation of a novel antibiotic |
| DE2819094A1 (en) * | 1977-05-10 | 1978-11-23 | Sandoz Ag | CYCLOSPORIN DERIVATIVES, THEIR USE AND MANUFACTURING |
| US4215199A (en) * | 1978-06-05 | 1980-07-29 | Sandoz Ltd. | Antibiotic production |
| SE448386B (en) * | 1978-10-18 | 1987-02-16 | Sandoz Ag | NEW CYCLOSPORIN DERIVATIVES, PROCEDURE FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITION CONTAINING THEM |
| DE3260468D1 (en) * | 1981-01-09 | 1984-09-06 | Sandoz Ag | Novel cyclosporins |
| JPS5877894A (en) * | 1981-11-05 | 1983-05-11 | Mitsui Toatsu Chem Inc | Removing method of protein |
| CH667274A5 (en) * | 1984-03-23 | 1988-09-30 | Sandoz Ag | CYCLOSPORINE, THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
| DE3888357T2 (en) * | 1987-06-22 | 1994-09-15 | Merck & Co Inc | Cyclosporin derivatives that carry a modified amino acid at position 8. |
| HU201577B (en) * | 1988-12-20 | 1990-11-28 | Gyogyszerkutato Intezet | Process for producing cyclosporin antibiotics |
| JPH02216453A (en) * | 1989-02-17 | 1990-08-29 | Sekisui Chem Co Ltd | Method for measuring cyclosporin |
| CA2101777A1 (en) * | 1991-01-25 | 1992-07-26 | Toshio Goto | Process for producing cyclosporin a and/or c |
| EP0507968B1 (en) * | 1991-04-06 | 1995-09-06 | Arzneimittelwerk Dresden Gmbh | Method for the fermentative production and isolation of cyclosporin A and new cyclosporin forming strains |
| HU213553B (en) * | 1992-05-25 | 1997-07-28 | Biogal Gyogyszergyar | Process for isolating of cyclosporin-a |
| FI92334C (en) * | 1992-12-30 | 1994-10-25 | Leiras Oy | Process for producing cyclosporins and new Tolypocladium strain useful in the process |
| FR2723846B1 (en) * | 1994-08-24 | 1997-06-13 | Hi Pharmtech | SOLID PHARMACEUTICAL FORM FOR THE ADMINISTRATION OF A LIPOSOLUBLE LIQUID ACTIVE SUBSTANCE |
| KR100304324B1 (en) * | 1994-10-13 | 2001-11-22 | 김용규 | Method for manufacturing cyclosporine a |
| KR0126610B1 (en) * | 1994-10-18 | 1997-12-29 | 김충환 | Producing method of cyclosporina by cell fusioned microorganism |
-
1996
- 1996-06-05 US US08/658,653 patent/US5747330A/en not_active Expired - Lifetime
-
1997
- 1997-03-05 US US08/810,077 patent/US5801020A/en not_active Expired - Lifetime
- 1997-06-05 DE DE69730497T patent/DE69730497D1/en not_active Expired - Lifetime
- 1997-06-05 WO PCT/IB1997/000654 patent/WO1997046580A1/en active IP Right Grant
- 1997-06-05 CA CA002257254A patent/CA2257254C/en not_active Expired - Fee Related
- 1997-06-05 AU AU29122/97A patent/AU2912297A/en not_active Abandoned
- 1997-06-05 AT AT97923272T patent/ATE275153T1/en not_active IP Right Cessation
- 1997-06-05 WO PCT/IB1997/000914 patent/WO1997046575A1/en not_active Application Discontinuation
- 1997-06-05 EP EP97923272A patent/EP0906336B1/en not_active Expired - Lifetime
- 1997-06-05 ES ES97923272T patent/ES2227693T3/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| AU2912297A (en) | 1998-01-05 |
| DE69730497D1 (en) | 2004-10-07 |
| WO1997046580A1 (en) | 1997-12-11 |
| US5801020A (en) | 1998-09-01 |
| ES2227693T3 (en) | 2005-04-01 |
| CA2257254A1 (en) | 1997-12-11 |
| EP0906336B1 (en) | 2004-09-01 |
| EP0906336A1 (en) | 1999-04-07 |
| US5747330A (en) | 1998-05-05 |
| ATE275153T1 (en) | 2004-09-15 |
| WO1997046575A1 (en) | 1997-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Murthy et al. | Cyclosporin-A production by Tolypocladium inflatum using solid state fermentation | |
| RU1836425C (en) | A way of obtaining the complex antibiotic cyclosporin and/or its components as well as the fungus strain tolypocladium varium | |
| CA2257254C (en) | Antibiotic producing microbe | |
| CA2152963C (en) | A process for producing immunosuppressives and a novel microbial species to be employed therein | |
| WO1994016091A9 (en) | A process for producing immunosuppressives and a novel microbial species to be employed therein | |
| Isaac et al. | Production of cyclosporins by Tolypocladium niveum strains | |
| Carú et al. | Isolation of infective and effective Frankia strains from root nodules of Alnus acuminata (Betulaceae) | |
| EP0781348B1 (en) | Process for manufacturing cyclosporin a by highly productive fusant strain | |
| EP0725076B1 (en) | A process for the preparation of cyclosporin A from tolypocladium species | |
| EP0846699A1 (en) | Substance wf16616, process for production thereof, and use thereof | |
| Lee et al. | Nutritional requirements and mass production of nematode-trapping fungus, Arthrobotrys oligospora | |
| JP4248485B2 (en) | Microorganisms and processes for the production of teicoplanin | |
| CN114164132A (en) | Achromobacter, application thereof and method for preparing phenazine-1-carboxylic acid and phenazine-1-formamide | |
| SI8912415A (en) | Microbial process for the production of immunosuppresive antibiotics |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20160606 |